Treatment of chronic hepatitis B infection: An update of Swedish recommendations

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 6-7, 2008, Pages 436-450

  Lindh, Magnus ^a   Uhnoo, Ingrid ^b   Blackberg, Joans ^c   Duberg, Ann Sofi ^d   Friman, Stybjorn ^a   Fischler, Bjorn ^e   Karlstrom, Olof ^e   Norkrans, Gunnar ^a   Reichard, Olle ^f   Sangfeldt, Per ^g   Soderstrom, Ann ^h   Sonnerborg, Anders ^e   Weiland, Ola ^e   Wejstål, Rune ^a   Wistrom, Johan ⁱ  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f Vasteras Hospital   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h Units for Communicable Disease Control   (Sweden)

ⁱ UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; DIDANOSINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STEROID; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; VIRUS DNA;

ANOREXIA; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; GENOTYPE; GROWTH RETARDATION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LOW DRUG DOSE; MIXED INFECTION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROGNOSIS; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; RECURRENT INFECTION; REVIEW; RISK REDUCTION; SEROCONVERSION; SIDE EFFECT; SURVIVAL RATE; SWEDEN; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; WEIGHT REDUCTION;

ADENINE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON ALFA-2A; LAMIVUDINE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; SWEDEN;

EID: 47349100200     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540802154769     Document Type: Review

References (55)

1. Lavanchy, D. (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 11, pp. 97-107.
2. Chu, CH, Liaw, YF, Sheen, IS and Chen, TJ. (1985) Correlation of age with the status of hepatitis B virus replication and histological changes in chronic type B hepatitis. Liver, 5, pp. 117-122.
3. Fattovich, G., Olivari, N., Pasino, M., D'Onofrio, M., Martone, E. and Donato, F. (2008) Long-term outcome of chronic hepatitis B in Caucasian patients: Mortality after 25 years. Gut, 57, pp. 84-90.
4. Hsu, YS, Chien, RN, Yeh, CT, Sheen, IS, Chiou, HY Chu, CM et al. (2002) Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology, 35, pp. 1522-1527.
5. Hannoun, C., Horal, P. and Lindh, M. (2000) Long-term mutation rates in the hepatitis B virus genome. J Gen Virol, 81, pp. 75-83.
6. Lindh, M., Horal, P., Dhillon, AP and Norkrans, G. (2000) Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat, 7, pp. 258-267.
7. Lindh, M., Hannoun, C., Dhillon, AP, Norkrans, G. and Horal, P. (1999) Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis, 179, pp. 775-782.
8. Chu, CJ, Hussain, M. and Lok, AS. (2002) Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology, 122, pp. 1756-1762.
9. Chan, HL, Hui, AY, Wong, ML, Tse, AM, Hung, LC Wong, VW et al. (2004) Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, pp. 1494-1498.
10. Kao, J., Chen, P., Lai, M. and Chen, D. (2000) Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology, 118, pp. 554-559.
11. Sanchez-Tapias, JM, Costa, J., Mas, A., Bruguera, M. and Rodes, J. (2002) Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology, 123, pp. 1848-1856.
12. Erhardt, A., Blondin, D., Hauck, K., Sagir, A., Kohnle, T. Heintges, T. et al. (2005) Response to interferon alfa is hepatitis B virus genotype dependent: Genotype A is more sensitive to interferon than genotype D. Gut, 54, pp. 1009-1013.
13. Chan, HL, Tsang, SW, Liew, CT, Tse, CH, Wong, ML Ching, JY et al. (2002) Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol, 97, pp. 406-412.
14. Chu, CJ, Hussain, M. and Lok, AS. (2002) Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology, 36, pp. 1408-1415.
15. Chen, CJ, Yang, HI, Su, J., Jen, CL, You, SL Lu, SN et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 295, pp. 65-73.
16. Iloeje, UH, Yang, HI, Su, J., Jen, CL, You, SL and Chen, CJ. (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 130, pp. 678-686.
17. Janssen, HL, van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, US Cakaloglu, Y. et al. (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet, 365, pp. 123-129.
18. Chan, HL, Leung, NW, Hui, AY, Wong, VW, Liew, CT Chim, AM et al. (2005) A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med, 142, pp. 240-250.
19. Lau, GK, Piratvisuth, T., Luo, KX, Marcellin, P., Thongsawat, S. Cooksley, G. et al. (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 352, pp. 2682-2695.
20. Marcellin, P., Lau, GK, Bonino, F., Farci, P., Hadziyannis, S. Jin, R. et al. (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 351, pp. 1206-1217.
21. Kao, JH, Wu, NH, Chen, PJ, Lai, MY and Chen, DS. (2000) Hepatitis B genotypes and the response to interferon therapy. J Hepatol, 33, pp. 998-1002.
22. Cooksley, WG, Piratvisuth, T., Lee, SD, Mahachai, V., Chao, YC Tanwandee, T. et al. (2003) Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat, 10, pp. 298-305.
23. Soderstrom, A., Lindh, M., Ekholm, K., Conradi, N., Horal, P. Krantz, M. et al. (2005) Predictive factors and virological response to interferon treatment in children with chronic hepatitis B. Scand J Infect Dis, 37, pp. 40-47.
24. ter Borg, MJ, van Zonneveld, M., Zeuzem, S., Senturk, H., Akarca, US Simon, C. et al. (2006) Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. Hepatology, 44, pp. 721-727.
25. Lai, CL, Chien, RN, Leung, NW, Chang, TT, Guan, R. Tai, DI et al. (1998) A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 339, pp. 61-68.
26. Liaw, YF, Sung, JJ, Chow, WC, Farrell, G., Lee, CZ Yuen, H. et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351, pp. 1521-1531.
27. Tipples, GA, Ma, MM, Fischer, KP, Bain, VG, Kneteman, NM and Tyrrell, DL. (1996) Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology, 24, pp. 714-717.
28. Marcellin, P., Chang, TT, Lim, SG, Tong, MJ, Sievert, W. Shiffman, ML et al. (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 348, pp. 808-816.
29. Hadziyannis, SJ, Tassopoulos, NC, Heathcote, EJ, Chang, TT, Kitis, G. Rizzetto, M. et al. (2005) Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med, 352, pp. 2673-2681.
30. Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W. Gibbs, C. et al. (2003) Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology, 125, pp. 292-297.
31. Hadziyannis, SJ, Tassopoulos, NC, Heathcote, EJ, Chang, TT, Kitis, G. Rizzetto, M. et al. (2006) Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology, 131, pp. 1743-1751.
32. Lee, YS, Suh, DJ, Lim, YS, Jung, SW, Kim, KM Lee, HC et al. (2006) Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology, 43, pp. 1385-1391.
33. Chang, TT, Gish, RG, de Man, R., Gadano, A., Sollano, J. Chao, YC et al. (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 354, pp. 1001-1010.
34. Lai, CL, Shouval, D., Lok, AS, Chang, TT, Cheinquer, H. Goodman, Z. et al. (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 354, pp. 1011-1020.
35. Westland, C., Delaney, Wt, Yang, H., Chen, SS, Marcellin, P. Hadziyannis, S. et al. (2003) Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology, 125, pp. 107-116.
36. Colonno, RJ, Rose, R., Baldick, CJ, Levine, S., Pokornowski, K. Yu, CF et al. (2006) Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology, 44, pp. 1656-1665.
37. Lai, CL, Gane, E., Liaw, YF, Hsu, CW, Thongsawat, S. Wang, Y. et al. (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 357, pp. 2576-2588.
38. van Bommel, F., Wunsche, T., Mauss, S., Reinke, P., Bergk, A. Schurmann, D. et al. (2004) Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 40, pp. 1421-1425.
39. van Bommel, F., Wunsche, T., Schurmann, D. and Berg, T. (2002) Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology, 36, pp. 507-508.
40. Lim, SG, Ng, TM, Kung, N., Krastev, Z., Volfova, M. Husa, P. et al. (2006) A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med, 166, pp. 49-56.
41. Calabrese, LH, Zein, NN and Vassilopoulos, D. (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis, 65, pp. 983-989.
42. Knoll, A., Boehm, S., Hahn, J., Holler, E. and Jilg, W. (2007) Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: High risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat, 14, pp. 478-483.
43. Lok, AS, Liang, RH, Chiu, EK, Wong, KL, Chan, TK and Todd, D. (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology, 100, pp. 182-188.
44. Lau, GK, Leung, YH, Fong, DY, Au, WY, Kwong, YL Lie, A. et al. (2002) High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood, 99, pp. 2324-2330.
45. Nunez, M. and Soriano, V. (2005) Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis, 5, pp. 374-382.
46. Terrault, N., Roche, B. and Samuel, D. (2005) Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl, 11, pp. 716-732.
47. Bortolotti, F., Guido, M., Bartolacci, S., Cadrobbi, P., Crivellaro, C. Noventa, F. et al. (2006) Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study. Hepatology, 43, pp. 556-562.
48. Ruiz-Moreno, M., Otero, M., Millan, A., Castillo, I., Cabrerizo, M. Jimenez, FJ et al. (1999) Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Hepatology, 29, pp. 572-575.
49. Lok, AS and Lai, CL. (1988) A longitudinal follow-up of asymptomatic hepatitis B surface antigen- positive Chinese children. Hepatology, 8, pp. 1130-1133.
50. Sokal, EM, Roberts, EA, Mieli-Vergani, G., McPhillips, P., Johnson, M. Barber, J. et al. (2000) A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother, 44, pp. 590-597.
51. Beasley, RP, Hwang, LY, Lee, GC, Lan, CC, Roan, CH Huang, FY et al. (1983) Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet, 2, pp. 1099-1102.
52. Ngui, SL, Andrews, NJ, Underhill, GS, Heptonstall, J. and Teo, CG. (1998) Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis, 27, pp. 100-106.
53. del Canho, R, Grosheide, PM, Mazel, JA, Heijtink, RA, Hop, WC Gerards, LJ et al. (1982) Ten-year neonatal hepatitis B vaccination program, The Netherlands, - 1992: Protective efficacy and long-term immunogenicity. Vaccine;15, 1997, pp. 1624-1630.
54. Soderstrom, A., Norkrans, G. and Lindh, M. (2003) Hepatitis B virus DNA during pregnancy and post partum: Aspects on vertical transmission. Scand J Infect Dis, 35, pp. 814-819.
55. Wong, VC, Ip, HM, Reesink, HW, Lelie, PN, Reerink-Brongers, EE Yeung, CY et al. (1984) Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet, 1, pp. 921-926.